MRI Dye Puts Kidney Patients at Risk

In February 2007, federal health officials warned doctors about the risk of a dangerous skin disease in kidney patients injected with gadolinium-based MRI dyes.

Gadolinium is a metallic substance used as a contrast agent in certain MRI dyes to provide a clearer picture of internal organs. Dyes containing gadolinium have been used since 1988 and there are currently five FDA approved gadolinium-based dyes on the market.

The FDA issued a public health advisory last year after reports surfaced in Europe linking gadolinium to a rare disease called nephrogenic systemic fibrosis. The disease has also been reported in more than two dozen dialysis patients in the United States.

A disease-tracking registry at Yale has recorded over 200 cases of nephrogenic systemic fibrosis. However, because the disease is so rare, experts suspect that it may go undiagnosed and thus underreported.

Injured by gadolinium? Contact a Gadolinium attorney for a complimentary case evaluation.

Enter Content Here

Gadolinium Contrast Agents Required to Include New Warning

The U.S. Food and Drug Administration (FDA) issued a news release Sept. 9, 2010, requiring that contrast agents containing gadolinium carry a new warning on their labels because it can lead to nephrogenic systemic fibrosis (NSF). Read More »

First Gadolinium Lawsuit Filed in U.S. Court

An Ohio woman has filed what is believed to be the first gadolinium lawsuit, claiming that the MRI dye Magnevist-made by Bayer-caused her 24-year-old son's death.
Read More »

Gadolinium-Based MRI Dyes Get Black Box Warning

The Food and Drug Administration has asked that a black box warning be added to all gadolinium-based MRI dyes to highlight the risk of nephrogenic systemic fibrosis, or NSF.
Read More »